General Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancersBy Healthcare Propulsion StaffSeptember 15, 20260 Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and…
